Norway In Vivo Cro Market Size & Outlook, 2023-2030

The in vivo cro market in Norway is expected to reach a projected revenue of US$ 79.4 million by 2030. A compound annual growth rate of 6.7% is expected of Norway in vivo cro market from 2024 to 2030.
Revenue, 2023 (US$M)
$50.5
Forecast, 2030 (US$M)
$79.4
CAGR, 2024 - 2030
6.7%
Report Coverage
Norway

Norway in vivo cro market highlights

  • The Norway in vivo cro market generated a revenue of USD 50.5 million in 2023 and is expected to reach USD 79.4 million by 2030.
  • The Norway market is expected to grow at a CAGR of 6.7% from 2024 to 2030.
  • In terms of segment, small molecule was the largest revenue generating modality type in 2023.
  • Large Molecule is the most lucrative modality type segment registering the fastest growth during the forecast period.


In vivo cro market data book summary

Market revenue in 2023USD 50.5 million
Market revenue in 2030USD 79.4 million
Growth rate6.7% (CAGR from 2023 to 2030)
Largest segmentSmall molecule
Fastest growing segmentLarge Molecule
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationSmall Molecule, Large Molecule
Key market players worldwideIQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group


Other key industry trends

  • In terms of revenue, Norway accounted for 1.1% of the global in vivo cro market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany in vivo cro market is projected to lead the regional market in terms of revenue in 2030.
  • Spain is the fastest growing regional market in Europe and is projected to reach USD 328.5 million by 2030.

Small molecule was the largest segment with a revenue share of 63.56% in 2023. Horizon Databook has segmented the Norway in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.


In Norway, in vivo CROs play a crucial role in preclinical development, providing invaluable assistance to clients in evaluating the safety and efficacy of potential drugs and therapies. These CROs offer a wide range of services, including study design, regulatory compliance, specialized imaging and monitoring, data analysis, and consultation.

By offering comprehensive solutions and expert guidance, they actively contribute to advancing preclinical research and enhancing the overall drug development pipeline. The commitment to upholding ethical standards, regulatory compliance, and fostering collaboration creates a favorable environment for in vivo CRO services. Consequently, domestic and international clients are eyeing the Norway market to seek reliable and high-quality preclinical research support.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

In Vivo CRO Market Companies

Name Profile # Employees HQ Website

Norway in vivo cro market size, by modality type, 2018-2030 (US$M)

Norway In Vivo CRO Market Outlook Share, 2023 & 2030 (US$M)

Norway in vivo cro market size, by modality type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more